PFE Pfizer Inc

   By Tess Stynes 
 

Pfizer Inc. (PFE) said its injectable drug for small-for-gestational-age children showed statistically significant increases in height after 24 months in a Phase 3B study.

The study was intended to generate additional data regarding the safety and efficacy of Genotropin in children born small-for-gestational-age who fail to achieve catch-up growth by two years of age.

In the study, which included children between ages 24 months and 30 months, those receiving the drug showed statistically significant improvement over those who didn't.

Genotropin has U.S. Food and Drug Administration approval to treat children who don't make enough growth hormone on their own, those with genetic conditions such as Prader-Willi syndrome and Turner syndrome, those born smaller than most other babies and those with idiopathic short stature. The drug also is approved for adults with growth hormone deficiency.

Write to Tess Stynes at tess.stynes@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires